- EBITDA (earnings before interest, taxes, depreciation and amortization, a non-GAAP measure) improvement of 73%, or $2.4 million;
- A 9% increase in total revenues, reflecting a 28% increase in Enzo Clinical Lab revenues for the period;
- Improved margins at both Enzo Labs and Enzo Life Sciences, resulting in a 17% increase in gross profits;
- A 54% reduction, or $2.5 million improvement, in the quarter’s net loss as compared to a year ago;
Enzo Biochem Reports Improved Third Quarter Results
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.